Amphastar Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$25.2M
Doctors Paid
1,443
Transactions
2,604
2024 Total
$1.0M
Payment Breakdown by Category
Research$25.1M (99.8%)
Food & Beverage$45,654 (0.2%)
Consulting$14,650 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25.1M | 194 | 99.8% |
| Food and Beverage | $45,654 | 2,408 | 0.2% |
| Consulting Fee | $14,650 | 2 | 0.1% |
Payments by Type
Research
$25.1M
194 transactions
General
$60,304
2,410 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phamacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients | $4.1M | 0 | 25 |
| Pharmacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients | $4.0M | 0 | 51 |
| API-A007-BE-PK/API-F007-BE-PK1p5/API-F007-BE-PK3p2 | $1.5M | 0 | 3 |
| A Randomized, Active-Controlled, Evaluator-Blinded, Crossover Study to Investigate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Tolerability of Intranasal (IN) Epinephrine (E005) in Healthy Volunteers | $1.4M | 0 | 1 |
| An Open-Label, Active-Controlled, Single Ascending Dose Study to Initially Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Intranasal (IN) Epinephrine (E005) in Healthy Volunteers | $1.3M | 0 | 1 |
| Pharmacokinetics (PK) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) 21 mcg/inhalation versus ATROVENT HFA Inhalation Aerosol 21 mcg/inhalation in Healthy Adult Volunteers | $1.3M | 0 | 1 |
| Pharmacokinetics Bioequivalence Study of Beclomethasone Dipropionate HFA MDI (Q001, 40 mcg/inhalation) versus QVAR Inhalation Aerosol (40 mcg/inhalation) and QVAR REDIHALER mcg/inhalation) in Healthy Adult Volunteers | $1.2M | 0 | 1 |
| API-A007-BE-PD | $1.1M | 0 | 26 |
| Pilot Bioequivalence (BE) Pharmacokinetics (PK) Study of Iron Sucrose Injection by Intravenous Infusion in Healthy Adult Volunteers | $1.0M | 0 | 3 |
| API-A007-BE-PD/API-E005-CL-D1 | $832,990 | 0 | 3 |
| Pharmacokinetics Bioequivalence Study of Beclomethasone Dipropionate HFA MDI (Q001, 80 mcg/inhalation) versus QVAR Inhalation Aerosol (80 mcg/inhalation) in Healthy Adult Volunteers | $767,421 | 0 | 1 |
| Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmonary Disease (COPD) | $678,681 | 0 | 15 |
| Bioequivalence (BE) Pharmacokinetics (PK) Study of Iron Sucrose Injection by Intravenous Infusion in Healthy Adult Volunteers | $666,697 | 0 | 2 |
| Pharmacokinetics (PK) Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation (A008) versus ProAir HFA Inhalation Aerosol 90 mcg/inhalation in Healthy Adult Volunteers | $622,932 | 0 | 1 |
| Pilot Clinical endpoints (CE) Bioequivalence (BE) study of Beclamethasone Dipropionate HFA MDI 40 mcg/inhalation versus QVAR Inhalation Aerosol 40 mcg/inhalation in asthma patients. A randomized double-dummy, placebo and active controlled, multiple-dose, 3-arm parallel study consisting of a 2 week run period followed by a 6 week treatment period | $555,262 | 0 | 9 |
| Pilot Clinical Pharmacodynamic (PD) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (A007) in Treatment for Chronic Obstructive Pulmonary Disease (COPD) | $437,902 | 0 | 14 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) Study of Ipratropium Bromide HFA MDI (internal code name A007) 21 mcg/inhalation versus ATROVENT HFA Inhalation Aerosol 21mcg/inhalation in Healthy Adult | $376,796 | 0 | 1 |
| Pharmacokinetic (PK) Study of Intranasal (IN) Naloxone HCl (N002) in Healthy Adult Volunteers: Influence of Runoff Volume on Partial AUC | $302,158 | 0 | 1 |
| Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.25mg) by Oral Inhalation, versus Epinephrine Injection (0.30mg) by IM and ProAir (0.18mg) by Oral Inhalation in Healthy Individuals | $266,022 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) study of Fluticasone Propionate and Salmeterol Xinafoate Dry Powder Inhaler versus Advair Diskus (250/50 mcg) in healthy adult volunteers. A randomized evaluator blinded, single-dose, two-treatment, two-period, two-sequence, crossover fasting study | $260,451 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) study of Fluticasone Propionate and Salmeterol Xinafoate Dry Powder Inhaler versus Advair Diskus (500/50 mcg) in healthy adult volunteers. A randomized, evaluator-blinded, single-dose, two-treatment, two-period, two-sequence, crossover, fasting study | $259,937 | 0 | 1 |
| PIlot Pharmacokinetics (PK) Bioequivalence (BE) study of Beclomethasone Dipropionate HFA MDI 80 mcg/inhalation versus QVAR Inhalation Aerosol (80 mcg/inhalation) in healthy adult volunteers. A randomized evaluator-blind, single-dose, two-treatment, two-period, two-sequence, crossover, fasting study | $243,915 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) study of Fluticasone Pripionate HFA MDI 220 mcg/inhalation versus Flovent HFA 220 mcg/inhalation in healthy adult volunteers. A randomized, evaluator-blinded, single-dose, two-treatment, two-period, two-sequence, crossover-fasting study | $238,834 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) study of Fluticasone Priponate HFA MDI 110 mcg/inhalation versus Flovent HFA 110 mcg/inhalation in healthy adult volunteers. A randomized, evaluator-blinded, single-dose, two-treatment, two-period, two sequence, crossover, fasting study | $215,035 | 0 | 1 |
| Study of Drug Exposure in Systemic Circulation of Primatene Mist (0.50mg) by Oral Inhalation, versus Epinephrine Injection (0.30mg) by IM and ProAir (0.18mg) by Oral Inhalation, in Healthy Individuals | $193,551 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI (A008) 90 mcg /inhalation versus ProAir HFA Inhalation Aerosol 90 mcg /inhalation in Healthy Adult Volunteers | $164,475 | 0 | 1 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI (A008) 90 mcg/inhalation versus ProAir HFA Inhalation Aerosol 90 mcg/inhalation in Healthy Adult Volunteers | $129,806 | 0 | 1 |
| Preliminary Pharmacodynamic (PD) Bronchodilatation Dose-Scale Bioequivalence (BE) Study of PROAIR HFA MDI Inhalation Aerosol 90 mcg/inhalation in Asthma Patients | $113,818 | 0 | 3 |
| Pilot Pharmacokinetics (PK) Bioequivalence (BE) Study of Beclomethasone Dipropionate HFA MDI , 40 mcg/inhalation versus QVAR Inhalation Aerosol (40 mcg/inhalation in healthy adult volunteers. A randomized, evaluator-blind, single-dose, two-treatment, two-period, two-sequence, crossover, fasting study | $108,232 | 0 | 1 |
| Study of Intranasal (IN) Naloxone HCl (N002) Effect on Olfactory Function in Healthy Adult Volunteers | $102,439 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Sujata Wagh, Md, MD | Specialist | Jacksonville, FL | $117.71 | $0 |
| Mr. David Kugler, D.o, D.O | Endocrinology, Diabetes & Metabolism | Smithtown, NY | $117.69 | $0 |
| Dr. Michael Shanik, M.d, M.D | Endocrinology, Diabetes & Metabolism | Smithtown, NY | $117.69 | $0 |
| Minh Mach, M.d, M.D | Specialist | Toluca Lake, CA | $116.70 | $0 |
| Heather Matthews, Arnp, ARNP | Nurse Practitioner | The Woodlands, TX | $116.21 | $0 |
| Stella Ilyayeva, Md, MD | Endocrinology, Diabetes & Metabolism | Rego Park, NY | $115.04 | $0 |
| Dr. Matin Sharafatkhah, M.d, M.D | Endocrinology, Diabetes & Metabolism | Brooklyn, NY | $112.60 | $0 |
| Dr. Boris Mazurov, M.d, M.D | Internal Medicine | Brooklyn, NY | $112.60 | $0 |
| Catherine Anastasopoulou, Md, MD | Endocrinology, Diabetes & Metabolism | Elkins Park, PA | $111.60 | $0 |
| Nissa Blocher, Md, MD | Endocrinology, Diabetes & Metabolism | Elkins Park, PA | $109.86 | $0 |
| Meagan Gruwell, Aprn, APRN | Nurse Practitioner | Scottsdale, AZ | $108.84 | $0 |
| Kay Win, M.d, M.D | Student in an Organized Health Care Education/Training Program | Philadelphia, PA | $107.77 | $0 |
| Allison Kemp, Pa-C, PA-C | Physician Assistant | Parker, CO | $105.15 | $0 |
| Wendy Bui, Pa-C, PA-C | Medical | Aurora, CO | $105.15 | $0 |
| James Neifing, Md, MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $100.59 | $0 |
| Jennifer Murdoch, Anp, ANP | Nurse Practitioner | Portland, OR | $100.59 | $0 |
| Damaris Vega, Md, MD | Endocrinology, Diabetes & Metabolism | Houston, TX | $99.78 | $0 |
| Dr. Sharmini Long, M.d, M.D | Internal Medicine | Lone Tree, CO | $99.56 | $0 |
| Dr. Paul Piper, Md, MD | Endocrinology, Diabetes & Metabolism | The Woodlands, TX | $99.47 | $0 |
| Amanda Carl | Family Medicine | New Wilmington, PA | $97.74 | $0 |
| Anna Sandstrom, Md, MD | Pediatric Endocrinology | Oxnard, CA | $96.98 | $0 |
| Denise Joffe, Md, MD | Endocrinology, Diabetes & Metabolism | Bryn Mawr, PA | $96.83 | $0 |
| Patrick Yudez, Pa-C, PA-C | Medical | Las Vegas, NV | $96.01 | $0 |
| Sherry Sussman, M.d, M.D | Endocrinology, Diabetes & Metabolism | Smithtown, NY | $95.26 | $0 |
| Ms. Daryana Aronova | Medical | Forest Hills, NY | $94.41 | $0 |
Ad
Top Products
- BAQSIMI $11,727
Payment Categories
- Food & Beverage $45,654
- Consulting $14,650
- Research $25.1M
About Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. has made $25.2M in payments to 1,443 healthcare providers, recorded across 2,604 transactions in the CMS Open Payments database. In 2024, the company paid $1.0M. The top product by payment volume is BAQSIMI ($11,727).
Payments were distributed across 66 medical specialties. The top specialty by payment amount is Allergy & Immunology ($15,787 to 3 doctors).
Payment categories include: Food & Beverage ($45,654), Consulting ($14,650), Research ($25.1M).